MiRNA Differences Related to Treatment-Resistant Schizophrenia

• Published in: International journal of molecular sciences 2023-01, Vol.24 (3), p.1891
• Main Authors: Pérez-Rodríguez, Daniel, Penedo, Maria Aránzazu, Rivera-Baltanás, Tania, Peña-Centeno, Tonatiuh, Burkhardt, Susanne, Fischer, Andre, Prieto-González, José M, Olivares, José Manuel, López-Fernández, Hugo, Agís-Balboa, Roberto Carlos
• Format: Article
• Language: English
• Subjects: Alzheimer's disease; Antipsychotic Agents - pharmacology; Antipsychotic Agents - therapeutic use; Antipsychotics; Biomarkers; Clustering; Drug Resistance - genetics; Gene expression; Humans; Kinases; MDM2 protein; Mental disorders; Metabolism; microRNA; MicroRNAs - genetics; MicroRNAs - therapeutic use; miRNA; p53; p53 Protein; Psychosis; Psychotropic drugs; Schizophrenia; Schizophrenia - diagnosis; Schizophrenia - drug therapy; Schizophrenia - genetics; Schizophrenia, Treatment-Resistant; SIRT1 protein; Transcription factors; treatment resistant schizophrenia
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms24031891

Schizophrenia (SZ) is a serious mental disorder that is typically treated with antipsychotic medication. Treatment-resistant schizophrenia (TRS) is the condition where symptoms remain after pharmacological intervention, resulting in long-lasting functional and social impairments. As the identification and treatment of a TRS patient requires previous failed treatments, early mechanisms of detection are needed in order to quicken the access to effective therapy, as well as improve treatment adherence. In this study, we aim to find a microRNA (miRNA) signature for TRS, as well as to shed some light on the molecular pathways potentially involved in this severe condition. To do this, we compared the blood miRNAs of schizophrenia patients that respond to medication and TRS patients, thus obtaining a 16-miRNA TRS profile. Then, we assessed the ability of this signature to separate responders and TRS patients using hierarchical clustering, observing that most of them are grouped correctly (~70% accuracy). We also conducted a network, pathway analysis, and bibliography search to spot molecular pathways potentially altered in TRS. We found that the response to stress seems to be a key factor in TRS and that proteins p53, SIRT1, MDM2, and TRIM28 could be the potential mediators of such responses. Finally, we suggest a molecular pathway potentially regulated by the miRNAs of the TRS profile.